RAD51 inhibitors and uses thereof
The present invention includes novel RAD51 inhibitors. The compounds of the invention may be useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
1. A compound selected from the group consisting of formula (I), formula (II), and formula (III), a salt or solvate, and any combinations thereof:
wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 21 , R 22 ,R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , and R 29 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, CN, NO 2 , OR 30 , SR 30 , S(═O)R 30 , S(═O) 2 R 30 , NHS(═O) 2 R 30 , C(═O)R 30 , OC(═O)R 30 , CO 2 R 30 , OCO 2 R 30 , CH(R 30 ) 2 , N(R 30 ) 2 , C(═O)N(R 30 ) 2 , OC(═O)N(R 30 ) 2 , NHC(═O)NH(R 30 ), NHC(═O)R 30 , NHC(═O)OR 30 , C(OH)(R 30 ) 2 , and C(NH 2 )(R 30 ) 2 ;
each occurrence of R 30 is independently selected from the group consisting of H and C 1 -C 6 alkyl;
Het is a 5- to 14-membered substituted or unsubstituted heteroaryl ring;
the bond between carbon 1 and carbon 2 may be a single bond or a double bond;
the bond between carbon 3 and carbon 4 may be a single bond or a double bond;
p is an integer from 0-3;
q is an integer from 1-3; and
r is an integer from 0-3,
with the proviso that in a compound of formula (II), if R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , and R 19 are all H, the bond between carbon 1 and carbon 2 is a double bond, and q is 0, or 1 then Het cannot be 3-indolyl.
2. The compound of claim 1 , wherein the compound is a compound of formula (I).
3. The compound of claim 2 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each H.
4. The compound of claim 1 , wherein Het is selected from the group consisting of indolyl, azaindolyl, and thiazolyl, wherein the indolyl, azaindolyl, or thiazolyl group may be optionally substituted.
5. The compound of claim 1 , wherein Het is selected from the group consisting of:
wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 7 , X 8 , and X 9 are each independently selected from the group consisting of N and CR 41 ;
X 6 and X 10 are each independently selected from the group consisting of S, O, C(R 42 ) 2 , and NR 43 ;
each occurrence of R 40 , R 41 , R 42 , and R 43 is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, CN, NO 2 , OR 44 , SR 44 , S(═O)R 44 , S(═O) 2 R 44 , NHS(═O) 2 R 44 , C(═O)R 44 , OC(═O)R 44 , CO 2 R 44 , OCO 2 R 44 CH(R 44 ) 2 , N(R 44 ) 2 , C(═O)N(R 44 ) 2 , OC(═O)N(R 44 ) 2 , NHC(═O)NH(R 44 ), NHC(═O)R 44 , NHC(═O)OR 44 , C(OH)(R 44 ) 2 , and C(NH 2 )(R 44 ) 2 ; and
each occurrence of R 44 is independently selected from the group consisting of H and C 1 -C 6 alkyl.
6. The compound of claim 5 , wherein at least one of X 1 , X 2 , or X 3 is NR 41 .
7. The compound of claim 5 , wherein Het is selected from the group consisting of:
8. The compound of claim 2 , wherein p is 1.
9. The compound of claim 1 , wherein the compound is selected from the group consisting of:
a salt or solvate, and any combinations thereof.
10. The compound of claim 1 , wherein the compound is:
a salt or solvate, and any combinations thereof.
11. A pharmaceutical composition comprising at least one compound of claim 1 .
12. A method of preventing or treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a compound selected from the group consisting of formula (I), formula (II), and formula (III), a salt or solvate, and any combinations thereof:
wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , and R 29 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, CN, NO 2 , OR 30 , SR 30 , S(═O)R 30 , S(═O) 2 R 30 , NHS(═O) 2 R 30 , C(═O)R 30 , OC(═O)R 30 , CO 2 R 30 , OCO 2 R 30 , CH(R 30 ) 2 , N(R 30 ) 2 , C(═O)N(R 30 ) 2 , OC(═O)N(R 30 ) 2 , NHC(═O)NH(R 30 ), NHC(═O)R 30 , NHC(═O)OR 30 , C(OH)(R 30 ) 2 , and C(NH 2 )(R 30 ) 2 ;
each occurrence of R 30 is independently selected from the group consisting of H and C 1 -C 6 alkyl;
Het is a 5- to 14-membered substituted or unsubstituted heteroaryl ring;
the bond between carbon 1 and carbon 2 may be a single bond or a double bond;
the bond between carbon 3 and carbon 4 may be a single bond or a double bond;
p is an integer from 0-3;
q is an integer from 1-3; and
r is an integer from 0-3,
with the proviso that in a compound of formula (II), if R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , and R 19 are all H, the bond between carbon 1 and carbon 2 is a double bond, and q is 0or 1, then Het cannot be 3-indolyl.
13. The method of claim 12 , wherein the compound is a compound of formula (I).
14. The method of claim 13 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each H.
15. The method of claim 12 , wherein Het is selected from the group consisting of indolyl, azaindolyl, and thiazolyl, wherein the indolyl, azaindolyl, or thiazolyl group may be optionally substituted.
16. The method of claim 12 , wherein Het is selected from the group consisting of:
wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 7 , X 8 , and X 9 are each independently selected from the group consisting of N and CR 41 ;
X 6 and X 10 are each independently selected from the group consisting of S, O, C(R 42 ) 2 , and NR 43 ;
each occurrence of R 40 , R 41 , R 42 , and R 43 is independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, CN, NO 2 , OR 44 , SR 44 , S(═O)R 44 , S(═O) 2 R 44 , NHS(═O) 2 R 44 , C(═O)R 44 , OC(═O)R 44 , CO 2 R 44 , OCO 2 R 44 , CH(R 44 ) 2 , N(R 44 ) 2 , C(═O)N(R 44 ) 2 , OC(═O)N(R 44 ) 2 , NHC(═O)NH(R 44 ), NHC(═O)R 44 , NHC(═O)OR 44 , C(OH)(R 44 ) 2 , and C(NH 2 )(R 44 ) 2 ; and
each occurrence of R 44 is independently selected from the group consisting of H and C 1 -C 6 alkyl.
17. The method of claim 16 , wherein at least one of X 1 , X 2 , or X 3 is NR 41 .
18. The method of claim 16 , wherein Het is selected from the group consisting of:
19. The method of claim 13 , wherein p is 1.
20. The method of claim 12 , wherein the compound is:
a salt or solvate and any combinations thereof.
21. A compound selected from the group consisting of formula (I) and formula (III), a salt or solvate, and any combinations thereof:
wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , and R 29 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, F, Cl, Br, I, CN, NO 2 , OR 30 , SR 30 , S(═O)R 30 , S(═O) 2 R 30 , NHS(═O) 2 R 30 , C(═O)R 30 , OC(═O)R 30 , CO 2 R 30 , OCO 2 R 30 , CH(R 30 ) 2 , N(R 30 ) 2 , C(═O)N(R 30 ) 2 , OC(═O)N(R 30 ) 2 , NHC(═O)NH(R 30 ), NHC(═O)R 30 , NHC(═O)OR 30 , C(OH)(R 30 ) 2 , and C(NH 2 )(R 30 ) 2 ;
each occurrence of R 30 is independently selected from the group consisting of H and C 1 -C 6 alkyl;
Het is a 5- to 14-membered substituted or unsubstituted heteroaryl ring;
the bond between carbon 3 and carbon 4 may be a single bond or a double bond;
p is an integer from 0-3; and
r is an integer from 0-3.